Annals of Hematology

, Volume 93, Issue 6, pp 1023–1029 | Cite as

Absolute lymphocyte count and risk of short-term infection in patients with immune thrombocytopenia

  • Ming-Hung Hu
  • Yuan-Bin Yu
  • Yu-Chung Huang
  • Jyh-Pyng Gau
  • Liang-Tsai Hsiao
  • Jin-Hwang Liu
  • Ming-Huang Chen
  • Tzeon-Jye Chiou
  • Po-Min Chen
  • Cheng-Hwai Tzeng
  • Chun-Yu Liu
Original Article


Patients with immune thrombocytopenia (ITP) may be at increased risk of infection because of the steroids and other immunosuppressive agents used in its treatment. This study aimed to identify events that are associated with infection within 6 months of diagnosis and the impact that infection has on survival. We retrospectively evaluated 239 patients (107 men, 132 women; median age 61 years) diagnosed between January 1997 and August 2011. Every patient received steroid treatment according to the platelet count and the extent of bleeding. Logistic regression analysis was used to identify risk factors associated with the development of infection within 6 months of ITP being diagnosed. Sixty-two patients (25.9 %) developed an infection within 6 months of diagnosis. Multivariate analysis revealed that a lower absolute lymphocyte count (ALC) at diagnosis (<1 × 109/l) was an independent risk factor for infection (P = 0.039; 95 % confidence interval, 1.033–3.599; odds ratio, 1.928). The time to infection event is significant shorter in those of low ALC, compared with those of higher ALC (P = 0.032). Furthermore, the 1-year mortality rate after ITP diagnosis was significantly higher in those patients who developed an infection (P = 0.001). ITP patients with a low absolute lymphocyte count at diagnosis have an increased risk of infection, and those who develop infections have lower 1-year survival.


Immune thrombocytopenia (ITP) Absolute lymphocyte count (ALC) Lymphopenia Infection 



This study was supported by the Taiwan Clinical Oncology Research Foundation and a grant from Taipei Veterans General Hospital V101A-004.

Conflict of interests

The authors declare no conflict of interest.


  1. 1.
    Portielje JE, Westendorp RG, Kluin-Nelemans HC et al (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549–2554PubMedCrossRefGoogle Scholar
  2. 2.
    Mazzucconi MG, Fazi P, Bernasconi S et al (2007) Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109:1401–1407PubMedCrossRefGoogle Scholar
  3. 3.
    Norgaard M, Jensen AO, Engebjerg MC et al (2011) Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood 117:3514–3520PubMedCrossRefGoogle Scholar
  4. 4.
    Daou S, Federici L, Zimmer J et al (2008) Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med 19:447–451PubMedCrossRefGoogle Scholar
  5. 5.
    Huang YC, Liu CJ, Liu CY et al (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 90:1145–1151PubMedCrossRefGoogle Scholar
  6. 6.
    Siddiqui M, Ristow K, Markovic SN et al (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134:596–601PubMedCrossRefGoogle Scholar
  7. 7.
    Cox MC, Nofroni I, Ruco L et al (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 49:1745–1751PubMedCrossRefGoogle Scholar
  8. 8.
    George JN, Woolf SH, Raskob GE et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40PubMedGoogle Scholar
  9. 9.
    Neunert C, Lim W, Crowther M et al (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207PubMedCrossRefGoogle Scholar
  10. 10.
    Godeau B, Chevret S, Varet B et al (2002) Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 359:23–29PubMedCrossRefGoogle Scholar
  11. 11.
    Cheng Y, Wong RS, Soo YO et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349:831–836PubMedCrossRefGoogle Scholar
  12. 12.
    Figueroa M, Gehlsen J, Hammond D et al (1993) Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 328:1226–1229PubMedCrossRefGoogle Scholar
  13. 13.
    Boruchov DM, Gururangan S, Driscoll MC et al (2007) Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 110:3526–3531PubMedCrossRefGoogle Scholar
  14. 14.
    Ghanima W, Godeau B, Cines DB et al (2012) How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 120:960–969PubMedCrossRefGoogle Scholar
  15. 15.
    Huang JJ, Jiang WQ, Lin TY et al (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22:149–155PubMedCrossRefGoogle Scholar
  16. 16.
    Hung MH, Yu YB, Hsiao LT et al (2013) Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin’s lymphoma with prior rituximab exposure. J Chin Med Assoc 76:195–200PubMedCrossRefGoogle Scholar
  17. 17.
    Oki Y, Yamamoto K, Kato H et al (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol 81:448–453PubMedCrossRefGoogle Scholar
  18. 18.
    Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393PubMedCrossRefGoogle Scholar
  19. 19.
    Panitsas FP, Theodoropoulou M, Kouraklis A et al (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103:2645–2647PubMedCrossRefGoogle Scholar
  20. 20.
    Wang T, Zhao H, Ren H et al (2005) Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90:914–923PubMedGoogle Scholar
  21. 21.
    Semple JW, Provan D (2012) The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol 19:357–362PubMedCrossRefGoogle Scholar
  22. 22.
    Semple JW (1998) Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424:41–45PubMedCrossRefGoogle Scholar
  23. 23.
    Nishimoto T, Satoh T, Takeuchi T et al (2012) Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol 40:279–289PubMedCrossRefGoogle Scholar
  24. 24.
    Aboul-Fotoh Lel M, Abdel Raheem MM, El-Deen MA et al (2011) Role of CD4+ CD25+ T cells in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 33:81–85CrossRefGoogle Scholar
  25. 25.
    Johnsen J (2012) Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012:306–312PubMedGoogle Scholar
  26. 26.
    Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120:187–193PubMedCrossRefGoogle Scholar
  27. 27.
    Semple JW (2002) Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 16:9–12PubMedCrossRefGoogle Scholar
  28. 28.
    Cines DB, Bussel JB, Liebman HA et al (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511–6521PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Blatt SP, Lucey CR, Butzin CA et al (1993) Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons. JAMA 269:622–626PubMedCrossRefGoogle Scholar
  30. 30.
    Shapiro NI, Karras DJ, Leech SH et al (1998) Absolute lymphocyte count as a predictor of CD4 count. Ann Emerg Med 32:323–328PubMedCrossRefGoogle Scholar
  31. 31.
    Napoli AM, Fischer CM, Pines JM et al (2011) Absolute lymphocyte count in the emergency department predicts a low CD4 count in admitted HIV-positive patients. Acad Emerg Med 18:385–389PubMedCrossRefGoogle Scholar
  32. 32.
    Napoli AM, Maughan B, Murray R et al (2013) Use of the relationship between absolute lymphocyte count and CD4 count to improve earlier consideration of pneumocystis pneumonia in HIV-positive emergency department patients with pneumonia. J Emerg Med 44:28–35PubMedCrossRefGoogle Scholar
  33. 33.
    Meibohm B, Derendorf H, Mollmann H et al (1999) Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther 37:367–376PubMedGoogle Scholar
  34. 34.
    Zweiman B, Atkins PC, Bedard PM et al (1984) Corticosteroid effects on circulating lymphocyte subset levels in normal humans. J Clin Immunol 4:151–155PubMedCrossRefGoogle Scholar
  35. 35.
    Ginsburg C, Guillevin L, Sauvaget F et al (1993) Systemic diseases treated by corticoids, plasma exchange and cyclophosphamide: infectious complications and lymphopenia. Ann Med Interne (Paris) 144:15–19Google Scholar
  36. 36.
    Craddock CG (1978) Corticosteroid-induced lymphopenia, immunosuppression, and body defense. Ann Intern Med 88:564–566PubMedCrossRefGoogle Scholar
  37. 37.
    Pamuk GE, Pamuk ON, Baslar Z et al (2002) Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 81:436–440PubMedCrossRefGoogle Scholar
  38. 38.
    Boren E, Gershwin ME (2004) Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 3:401–406PubMedCrossRefGoogle Scholar
  39. 39.
    Prelog M (2006) Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev 5:136–139PubMedCrossRefGoogle Scholar
  40. 40.
    Hasler P, Zouali M (2005) Immune receptor signaling, aging, and autoimmunity. Cell Immunol 233:102–108PubMedCrossRefGoogle Scholar
  41. 41.
    Cohen YC, Djulbegovic B, Shamai-Lubovitz O et al (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160:1630–1638PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Ming-Hung Hu
    • 1
    • 3
    • 5
  • Yuan-Bin Yu
    • 1
    • 3
  • Yu-Chung Huang
    • 1
    • 3
    • 4
  • Jyh-Pyng Gau
    • 1
    • 3
  • Liang-Tsai Hsiao
    • 1
    • 3
  • Jin-Hwang Liu
    • 1
    • 3
  • Ming-Huang Chen
    • 1
    • 3
  • Tzeon-Jye Chiou
    • 2
    • 3
  • Po-Min Chen
    • 1
    • 3
  • Cheng-Hwai Tzeng
    • 1
    • 3
  • Chun-Yu Liu
    • 1
    • 3
  1. 1.Division of Haematology and Oncology, Department of MedicineTaipei Veterans General HospitalTaipei CityRepublic of China
  2. 2.Division of Transfusion Medicine, Department of MedicineTaipei Veterans General HospitalTaipeiRepublic of China
  3. 3.National Yang-Ming University School of MedicineTaipeiRepublic of China
  4. 4.Division of Haematology and Oncology, Department of MedicineTaoyuan Veterans HospitalTaoyuan CityRepublic of China
  5. 5.Division of Haematology and Oncology, Department of MedicineCardinal Tien HospitalNew Taipei CityTaiwan

Personalised recommendations